X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES GLENMARK PHARMA JUBILANT LIFE SCIENCES/
GLENMARK PHARMA
 
P/E (TTM) x 12.2 12.7 95.9% View Chart
P/BV x 1.7 2.3 75.6% View Chart
Dividend Yield % 0.7 0.5 147.2%  

Financials

 JUBILANT LIFE SCIENCES   GLENMARK PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-18
GLENMARK PHARMA
Mar-18
JUBILANT LIFE SCIENCES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,039930 111.7%   
Low Rs600517 116.0%   
Sales per share (Unadj.) Rs482.6322.6 149.6%  
Earnings per share (Unadj.) Rs40.728.5 142.9%  
Cash flow per share (Unadj.) Rs67.439.2 171.9%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %0.40.3 132.5%  
Book value per share (Unadj.) Rs262.3183.0 143.3%  
Shares outstanding (eoy) m155.79282.17 55.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.72.2 75.7%   
Avg P/E ratio x20.125.4 79.2%  
P/CF ratio (eoy) x12.218.5 65.9%  
Price / Book Value ratio x3.14.0 79.0%  
Dividend payout %7.47.0 104.9%   
Avg Mkt Cap Rs m127,670204,206 62.5%   
No. of employees `0002.413.7 17.8%   
Total wages/salary Rs m15,55918,718 83.1%   
Avg. sales/employee Rs Th30,861.46,636.8 465.0%   
Avg. wages/employee Rs Th6,387.01,364.7 468.0%   
Avg. net profit/employee Rs Th2,604.4586.1 444.4%   
INCOME DATA
Net Sales Rs m75,17891,031 82.6%  
Other income Rs m400914 43.8%   
Total revenues Rs m75,57991,945 82.2%   
Gross profit Rs m15,18416,154 94.0%  
Depreciation Rs m4,1513,019 137.5%   
Interest Rs m2,8432,856 99.5%   
Profit before tax Rs m8,59111,193 76.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2473,155 71.2%   
Profit after tax Rs m6,3448,039 78.9%  
Gross profit margin %20.217.7 113.8%  
Effective tax rate %26.228.2 92.8%   
Net profit margin %8.48.8 95.6%  
BALANCE SHEET DATA
Current assets Rs m31,89869,887 45.6%   
Current liabilities Rs m20,04732,879 61.0%   
Net working cap to sales %15.840.7 38.8%  
Current ratio x1.62.1 74.9%  
Inventory Days Days6881 83.0%  
Debtors Days Days5593 58.7%  
Net fixed assets Rs m60,71528,892 210.1%   
Share capital Rs m156282 55.2%   
"Free" reserves Rs m40,71051,353 79.3%   
Net worth Rs m40,86551,635 79.1%   
Long term debt Rs m30,47841,418 73.6%   
Total assets Rs m96,176125,954 76.4%  
Interest coverage x4.04.9 81.8%   
Debt to equity ratio x0.70.8 93.0%  
Sales to assets ratio x0.80.7 108.2%   
Return on assets %9.68.6 110.4%  
Return on equity %15.515.6 99.7%  
Return on capital %16.015.1 106.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,40236,317 39.7%   
Fx outflow Rs m12,0449,720 123.9%   
Net fx Rs m2,35826,598 8.9%   
CASH FLOW
From Operations Rs m13,03216,481 79.1%  
From Investments Rs m-6,177-10,133 61.0%  
From Financial Activity Rs m-9,011-4,685 192.3%  
Net Cashflow Rs m-2,1231,770 -119.9%  

Share Holding

Indian Promoters % 45.6 48.3 94.4%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 6.9 126.1%  
FIIs % 21.2 34.4 61.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 10.5 201.0%  
Shareholders   23,815 56,727 42.0%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  ELDER PHARMA  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Jul 19, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - IPCA LABS COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS